Table 2. In vivo tumorigenic potential of ahMNCs.
| Mice | Cells | Age | Route a | Cell No. | Cell form | Event b | Number of mice | Median Survivals c |
|---|---|---|---|---|---|---|---|---|
| Neonate NOG | Negative | 1 week | I.C. | - | Only HBSS | None | 10 | >180 |
| Neonate NOG | Negative | 1 week | S.C. | - | Only HBSS | None | 10 | >180 |
| Neonate NOG | U87MG | 1 week | I.C. | 2×105 | w/ HBSS | Debility | 10 | 21 |
| Neonate NOG | U87MG | 1 week | S.C. | 2×106 | w/ HBSS | Neoplasm | 10 | 42 |
| Neonate NOG | 682TL | 1 week | I.C. | 2×105 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | 682TL | 1 week | S.C. | 2×106 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | hTERT-682TL | 1 week | I.C. | 2×105 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | hTERT-682TL | 1 week | S.C. | 2×106 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | 779TL | 1 week | I.C. | 2×105 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | 779TL | 1 week | S.C. | 2×106 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | hTERT-779TL | 1 week | I.C. | 2×105 | w/ HBSS | None | 10 | >180 |
| Neonate NOG | hTERT-779TL | 1 week | S.C. | 2×106 | w/ HBSS | None | 10 | >180 |
a. I.C.: Intracranial injection, S.C.: Subcutaneous injection
b. None: Not happened anything, Debility: decrease of weight and bad condition, Neoplasm: neoplasm into injection site
c. I.C. survivals: Condition and body weight, S.C. survivals: tumor volume ≥ 1,500 mm3